A novel JAK1 mutation identified in a patient with severe atopic dermatitis phenotype: Mechanistic insights and IL-4Rα targeted therapy.
Yutong Zhu, Shi Yan, Xiaoying Zhou et al.
✦ AI-curated · Sources linked
Case in brief
A child with early-onset severe atopic dermatitis presented with eosinophilia, elevated IgE, and growth retardation. Genetic analysis identified a novel JAK1 gain-of-function mutation (p.L783F). Functional assays indicated hyperactivation of the JAK-STAT pathway. Treatment with dupilumab led to significant improvement in skin lesions, pruritus, eosinophilia, and hyper-IgE, highlighting the effectiveness of targeted therapy.
What made this case unusual
This case presents a novel JAK1 mutation in a pediatric patient, expanding the known clinical spectrum of JAK1 gain-of-function mutations associated with immune dysregulation.
Diagnostic / clinical pearl
Clinicians should consider JAK1 gain-of-function mutations in pediatric patients with severe atopic dermatitis and associated immune dysregulation.
Why it matters
This case underscores the potential for targeted therapies like dupilumab in managing complex immune dysregulation in children with specific genetic mutations.